Effect of icosapent ethyl on stroke risk: Different strokes for different folks?

In the Reduction of Cardiovascular Events with Icosapent Ethyl –Intervention Trial (REDUCE-IT) [1], among patients with elevated triglycerides on statins, ischemic event risk was lower among those who received icosapent ethyl vs. placebo. However, while coronary events were reduced in both REDUCE-IT and another pure EPA trial, Japan EPA lipid intervention stu dy (JELIS) [2], ischemic stroke risk was lowered in REDUCE-IT (HR 0.64, 0.49-0.85), but not decreased in JELIS (HR 0.97, 0.85-1.10). The discrepancy between these two pure EPA trials might be due to the varied race-ethnicity composition of participants, since participants in REDUCE-IT were mostly fr om the USA and Europe, while those in JELIS were all from Japan.
Source: Journal of the Neurological Sciences - Category: Neurology Authors: Tags: Letter to the Editor Source Type: research